Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease

Domingues, Inês; Michalowski, Cecília Bohns; Marotti, Valentina; Zhang, Wunan; Hul, Matthias Van; Cani, Patrice D.; Leclercq, Isabelle; Beloqui, Ana

doi:10.1016/j.jconrel.2023.03.012

Journal of Controlled Release

2023

DOI: 10.1016/j.jconrel.2023.03.012

|View full text |Cite

Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease

Inês Domingues

Cecília Bohns Michalowski

Valentina Marotti

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease

Domingues,

Yagoubi,

Zhang

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent chronic liver disease that can progress to end-stage conditions with life-threatening complications, but no pharmacologic therapy has been approved. Drug delivery systems such as lipid nanocapsules (LNC) are very versatile platforms that are easy to produce and can induce the secretion of the native glucagon-like peptide 1 (GLP-1) when orally administered. GLP-1 analogs are currently being studied in clinical trials in the context of MASLD. Our nanosystem provides with increased levels of the native GLP-1 and increased plasmatic absorption of the encapsulated GLP-1 analog (semaglutide). Our goal was to use our strategy to demonstrate a better outcome and a greater impact on the metabolic syndrome associated with MASLD and on liver disease progression with our strategy compared with the oral marketed version of semaglutide, Rybelsus®. Therefore, we studied the effect of our nanocarriers on a dietary mouse model of MASLD, the Western diet model, during a daily chronic treatment of 4 weeks. Overall, the results showed a positive impact of semaglutide-loaded lipid nanocapsules towards the normalization of glucose homeostasis and insulin resistance. In the liver, there were no significant changes in lipid accumulation, but an improvement in markers related to inflammation was observed. Overall, our strategy had a positive trend on the metabolic syndrome and at reducing inflammation, mitigating the progression of the disease. Oral administration of the nanosystem was more efficient at preventing the progression of the disease to more severe states when compared to the administration of Rybelsus®, as a suspension. Graphical abstract

show abstract

Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease

Domingues,

Yagoubi,

Zhang

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

show abstract

Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease

Chen,

Beloqui,

2023

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery

Domingues,

Leclercq,

Beloqui

2023

Journal of Controlled Release

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease

Cited by 4 publications

References 24 publications

Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease

Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease

Oral nanomedicine biointeractions in the gastrointestinal tract in health and disease

Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery

Contact Info

Product

Resources

About